Program
Friday, 28th September, 2018
| 08.30 – 08.35 | Welcome and Congress opening |
| Jörg Fuchs and Rupert Handgretinger (Tuebingen, Germany) | |
| Session I: Pathology and Epidemiology | |
| Chair: G. Bisogno (Padana, Italy), R. Handgretinger (Tuebingen, Germany) | |
| 08.35 – 08.50 | New risk-stratification and new subtypes of RMS Christian Vokuhl (Kiel, Germany) |
| 08.50 – 09.05 | DSRCT in children, adolescents and young adults - characteristics and first-line therapies Monika Scheer (Stuttgart, Germany) |
| 09.05 – 09-20 | Synovial sarcoma in children and AYA: is it time for a composite risk factors classification? Daniel Orbach (Paris, France) |
| 09.20 – 09.35 | Relapses of RMS initially diagnosed in infancy Monika Sparber-Sauer (Stuttgart, Germany) |
| 09.35 – 09.50 | Building data commons to support pediatric cancer research Samuel Volchenboum (Chicago, USA) |
| 09.50 – 10.00 | Molecular characterization of inflammatory myofibroblastic tumors and the first experience of therapy with ALK inhibitor crizotinib in unresectable cases Amina Suleymanova (Moscow, Russia) |
| 10.00 – 10.30 | Coffee Break |
| Session II: Clinical trials and International Cooperation | |
| Chair: T. Klingebiel (Frankfurt, Germany), J. Chisholm (London, UK) | |
| 10.30 – 10.45 | Rhabdomyosarcoma without borders Gianni Bisogno (Padova, Italy) |
| 10.45 – 11.00 | The Frontline and Relapse in Rhabdomyosarcoma Study: FaR-RMS Meriel Jenney (Cardiff, UK) |
| 11.00 – 11.15 | New developments in NRSTS – The COG experience Sheri Spunt (Palo Alto, USA) |
| 11.15 – 11.30 | New trials on RMS (COG) Carola Arndt (Rochester, USA) |
| 11.30 – 11.45 | Report from INSTRUCT meeting Tuebingen 2018 Ewa Koscielniak (Stuttgart, Germany) |
| 11.45 – 12.00 | COG ARST14B1: Targeted Sequencing Validation Study of Pediatric Rhabdomyosarcoma Javed Khan (Bethesda, USA) |
| 12.00 – 12.10 | Tumor necrosis following neoadjuvant chemotherapy for synovial sarcoma: A report from Children’s Oncology Group study ARST0332 Rajkumar Venkatramani (Houston, USA) |
| 12.10 – 13.00 | Lunch |
| Session III: Tumor Biology, Genetics, Basic Research | |
| Chair: A. Hayes-Jordan (Houston, USA), S. Gottschalk (Memphis, USA) | |
| 13.00 – 13.15 | Epigenomic landscape of Rhabdomyosarcoma Javed Khan (Bethesda, USA) |
| 13.15 – 13.30 | From bench to bedside: cellular and molecular origins of RMS Simone Hettmer (Freiburg, Germany) |
| 13.30 – 13.45 | Molecular Pathology of Rhabdomyosarcoma Janet Shipley (Sutton, UK) |
| 13.45 – 14.00 | Rhabdomyosarcoma: an endothelial identity crisis Mark Hatley (Memphis, USA) |
| 14.00 – 14.15 | Immunotherapy of Rhabdomyosarcoma Javed Khan (Bethesda, USA) |
| 14.15 – 14.30 | CAR T-cell therapy for sarcoma Stephen Gottschalk (Memphis, USA) |
| 14.30 – 14.45 | Local tumor irradiation to enhance immunotherapy of Rhabdomyosarcoma Franziska Eckert (Tuebingen, Germany) |
| 14.45 – 15.00 | Harnessing PAX3-FOXO1 biology to identify new vulnerabilities for rhabdomyosarcoma Beat Schaefer (Zurich, Switzerland) |
| 15.00 – 15.10 | Glycine metabolism - a new interface for the treatment of alveolar rhabdomyosarcoma Anna Adamus (Marburg, Germany) |
| 15.10 – 15.30 | Coffee Break |
| Session IV: Relapses, Stage IV Disease, New Treatment Options | |
| Chair: H. Mandeville (Sutton, UK), E. Koscielniak (Suttgart, Germany) | |
| 15.30 – 15.45 | Relapses in RMS Carola Arndt (Rochester, USA) |
| 15.45 – 16.00 | FaR-RMS relapse study – a framework for the introduction of targeted agents in RMS Julia Chisholm (London, UK) |
| 16.00 – 16.15 | Non-RMS STS: challenges of treatment and new perspectives Andrea Ferrari (Padova, Italy) |
| 16.15 – 16.30 | Metastatic RMS – future perspectives Thomas Klingebiel (Frankfurt, Germany) |
| 16.30 – 16.45 | Novel antibody constructs for the treatment of sarcoma Rupert Handgretinger (Tuebingen, Germany) |
| 16.45 – 17.00 | Clinical trials for RMS/STS – Incorporating novel agents: from biology to clinical application Susanne Gatz (Sutton, UK) |
| 17.00 – 17.10 | Improved Survival After HLA Mismatched versus HLA matched Allogeneic Stem Cell Transplantation Implicates Presence Of A Graft Versus Tumor Effect In Ewing Sarcoma Patients with advanced Disease Uwe Thiel (Munich, Germany) |
| 17.10 – 17.20 | AMORE treatment as salvage treatment in children with relapsed head-neck rhabdomyosarcoma Bas Vaarwerk (Amsterdam, The Netherlands) |